Cargando…

Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake

Prognosis is generally poor for patients with pancreatic ductal adenocarcinoma. However, patients with germline BRCA1 or BRCA2 mutations (gBRCAm) may benefit from first-line platinum-based chemotherapy and maintenance therapy with the poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golan, Talia, Casolino, Raffaella, Biankin, Andrew V., Hammel, Pascal, Whitaker, Kristen D., Hall, Michael J., Riegert-Johnson, Douglas L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504836/ https://www.ncbi.nlm.nih.gov/pubmed/37720496 http://dx.doi.org/10.1177/17588359231189127

Ejemplares similares

A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing
por: Paiella, S., et al.
Publicado: (2023)

Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care
por: Casolino, Raffaella, et al.
Publicado: (2022)

Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward
por: Casolino, Raffaella, et al.
Publicado: (2021)

Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
por: Boursi, Ben, et al.
Publicado: (2023)

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
por: Hammel, P, et al.
Publicado: (2019)

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
por: Stossel, Chani, et al.
Publicado: (2023)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

Turnaround - analysis
por: Venturini Delsolaro, W
Publicado: (2012)

Prevalence of BRCA1 and BRCA2 germline variants in an unselected pancreatic cancer patient cohort in Pakistan
por: Muhammad, Noor, et al.
Publicado: (2023)

Molecular Subtyping and Precision Medicine for Pancreatic Cancer
por: Froeling, Fieke E. M., et al.
Publicado: (2021)

Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer
por: Henouda, Sarra, et al.
Publicado: (2016)

COVID-19 provides an opportunity to transform cancer research
por: Casolino, Raffaella, et al.
Publicado: (2021)

Project and program turnaround
por: Pavelko, Thomas
Publicado: (2016)

Corporate Turnaround Artistry
por: Sands, Jeff
Publicado: (2020)

COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore
por: Zhang, Zewen, et al.
Publicado: (2023)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
por: Casolino, Raffaella, et al.
Publicado: (2021)

Turnaround - Analysis and possible Improvements
por: Fuchsberger, K
Publicado: (2017)

The Diabetes 2-Month Turnaround
por: Scibilia, Renza
Publicado: (2017)

Improving theatre turnaround time
por: Fletcher, Daniel, et al.
Publicado: (2017)

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
por: Mukherjee, Shibani, et al.
Publicado: (2020)

An Important and Often Ignored Turnaround Time in Radiology – Clinician Turnaround Time: Implications for Musculoskeletal Radiology
por: Mayer, Michael, et al.
Publicado: (2019)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake
por: Ramsey, Mitchell L., et al.
Publicado: (2022)

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
por: Stegel, Vida, et al.
Publicado: (2011)

Early infant diagnosis of HIV in Myanmar: call for innovative interventions to improve uptake and reduce turnaround time
por: Thiha, Soe, et al.
Publicado: (2017)

Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
por: Casolino, R., et al.
Publicado: (2021)

Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review
por: Halpern, Naama, et al.
Publicado: (2020)

Implementing turnaround strategies as an entrepreneurial process
por: Baliouskas, Peter, et al.
Publicado: (2022)

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer
por: Golan, Talia, et al.
Publicado: (2017)

Evaluation of Laboratory Performance, Associated Factors and Staff Awareness Towards Achieving Turnaround Time in Tertiary Hospitals, Ethiopia
por: Gebreyes, Mebrat, et al.
Publicado: (2020)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
por: Vos, Shoko, et al.
Publicado: (2017)

Melanoma predisposition—A limited role for germline BRCA1 and BRCA2 variants
por: Adams, David J., et al.
Publicado: (2019)

Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9t6f0pbjnccrqes3n6b6e2h5nq